Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 18k
4 October 2019
Question for written answer E-003121-19
to the Commission
Rule 138
Bernd Lange (S&D)

 Subject:  Distortion of competition by DocMorris business model
 Answer in writing 

The DocMorris mail-order pharmacy, with its registered office in the Netherlands close to the border with Germany, sells exclusively to customers in Germany. Being located in the Netherlands, it is not subject to German laws governing mail-order pharmacies. In addition, customers have been misled by illegal use of a German shipping address. Furthermore, since the business is not registered in the Netherlands as a pharmacy, it is not, to the best of my knowledge, being monitored by the Dutch authorities.

1. What view does the Commission take of this business model involving unlawful use of a German shipping address, not to mention the absence of official scrutiny?

2. What is its assessment of its resulting competitive advantage vis-à-vis German pharmacies and what measures could be taken to prevent this distortion of competition?

3. Does it know whether DocMorris is in fact subject to official scrutiny in the Netherlands?

Original language of question: DE 
Last updated: 22 October 2019Legal notice - Privacy policy